Green Alpha Advisors LLC Buys 111,728 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Green Alpha Advisors LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 166.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 178,873 shares of the company's stock after purchasing an additional 111,728 shares during the quarter. Recursion Pharmaceuticals comprises 1.0% of Green Alpha Advisors LLC's investment portfolio, making the stock its 28th largest holding. Green Alpha Advisors LLC's holdings in Recursion Pharmaceuticals were worth $946,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $99,152,000. Novo Holdings A S acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $68,375,000. Geode Capital Management LLC grew its holdings in Recursion Pharmaceuticals by 12.1% during the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after purchasing an additional 655,238 shares in the last quarter. Finally, Norges Bank acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at approximately $23,429,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on RXRX shares. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Leerink Partners dropped their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Stock Down 4.1%

Shares of NASDAQ:RXRX traded down $0.20 during midday trading on Thursday, hitting $4.71. 21,047,809 shares of the stock were exchanged, compared to its average volume of 22,803,336. The company has a market capitalization of $1.91 billion, a PE ratio of -3.08 and a beta of 0.84. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The business's fifty day simple moving average is $4.82 and its two-hundred day simple moving average is $6.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. During the same period last year, the business earned ($0.39) earnings per share. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.